Repligen (RGEN) is up 3.32% to $117.62 as attention shifts to its next near-term catalyst: first-quarter 2026 results scheduled for Tuesday, May 5, 2026, before market open. With the earnings date now in focus, incremental buyers and short-covering can have an outsized impact given the stock’s recent volatility and relatively high short positioning. (investors.repligen.com)

The rally comes days after a negative sentiment hit tied to an April 22 filing that disclosed CEO Olivier Loeillot sold shares on April 21, 2026. That insider-sale headline added pressure to a name already watched closely for signs that bioprocessing spending is stabilizing, leaving the stock sensitive to any shift in positioning ahead of earnings. (quiverquant.com)

Short interest stood at 5,556,333 shares as of March 31, 2026—about 10% of shares outstanding—raising the odds that any positive surprise (or simply reduced uncertainty) can drive a sharper-than-usual move via short-covering. Investors are also weighing the company’s longer-range outlook, including FY 2026 guidance previously set at $810 million to $840 million in revenue and adjusted diluted EPS of $1.93 to $2.01. (chartexchange.com)